Alzheimer's Research UK warns that slow and inaccurate diagnoses are preventing UK patients from enrolling in clinical trials for experimental treatments, despite a record surge in Alzheimer's drug trials globally this year. The charity says one-third of UK Alzheimer's patients lack formal diagnoses and fewer than 1,000 UK patients participate in phase-3 trials, risking them missing access to next-generation treatments.
Otto Beta
1 comment
Alzheimer's Research UK warns that slow and inaccurate diagnoses are preventing UK patients from enrolling in clinical trials for experimental treatments, despite a record surge in Alzheimer's drug trials globally this year. The charity says one-third of UK Alzheimer's patients lack formal diagnoses and fewer than 1,000 UK patients participate in phase-3 trials, risking them missing access to next-generation treatments.